Almutairy Ali, Alhamed Abdullah, Grant Stephen G, Sarachine Falso Miranda J, Day Billy W, Simmons Colton R, Latimer Jean J
bioRxiv. 2024 Feb 16:2024.02.13.580215. doi: 10.1101/2024.02.13.580215.
Breast cancer (BC) is the most common cancer affecting women in the United States. Ductal carcinoma (DCIS) is the earliest identifiable pre-invasive BC lesion. Estimates show that 14 to 50% of DCIS cases progress to invasive BC. Our objective was to identify nuclear matrix proteins (NMP) with specifically altered expression in DCIS and later stages of BC compared to non-diseased breast reduction mammoplasty and a contralateral breast explant using mass spectrometry and RNA sequencing to accurately identify aggressive DCIS. Sixty NMPs were significantly differentially expressed between the DCIS and non-diseased breast epithelium in an isogenic contralateral pair of patient-derived extended explants. Ten of the sixty showed significant mRNA expression level differences that matched the protein expression. These 10 proteins were similarly expressed in non-diseased breast reduction cells. Three NMPs (RPL7A, RPL11, RPL31) were significantly upregulated in DCIS and all other BC stages compared to the matching contralateral breast culture and an unrelated non-diseased breast reduction culture. RNA sequencing analyses showed that these three genes were upregulated increasingly with BC progression. Finally, we identified three NMPs (AHNAK, CDC37 and DNAJB1) that were significantly downregulated in DCIS and all other BC stages compared to the isogenically matched contralateral culture and the non-diseased breast reduction culture using both proteomics and RNA sequencing techniques.
乳腺癌(BC)是美国影响女性的最常见癌症。导管原位癌(DCIS)是最早可识别的浸润前乳腺癌病变。据估计,14%至50%的DCIS病例会发展为浸润性乳腺癌。我们的目标是通过质谱分析和RNA测序,识别与非病变的乳房缩小整形术及对侧乳房外植体相比,在DCIS和乳腺癌后期阶段表达有特异性改变的核基质蛋白(NMP),以准确识别侵袭性DCIS。在一对同基因的患者来源的扩展外植体中,DCIS与非病变的乳腺上皮之间有60种NMP存在显著差异表达。这60种中的10种显示出与蛋白质表达相匹配的显著mRNA表达水平差异。这10种蛋白质在非病变的乳房缩小细胞中也有类似表达。与匹配的对侧乳房培养物和无关的非病变乳房缩小培养物相比,三种NMP(RPL7A、RPL11、RPL31)在DCIS和所有其他乳腺癌阶段显著上调。RNA测序分析表明,这三个基因随着乳腺癌进展上调程度越来越大。最后,我们使用蛋白质组学和RNA测序技术,识别出三种NMP(AHNAK、CDC37和DNAJB1),与同基因匹配的对侧培养物和非病变的乳房缩小培养物相比,它们在DCIS和所有其他乳腺癌阶段显著下调。